IPCALAB

Ipca Laboratories Share Price

 

 

Invest in Ipca Laboratories with 3.24X leverage

Invest with MTF

Performance

  • Low
  • ₹1,416
  • High
  • ₹1,464
  • 52 Week Low
  • ₹1,168
  • 52 Week High
  • ₹1,756
  • Open Price₹1,450
  • Previous Close₹1,455
  • Volume237,723

Investment Returns

  • Over 1 Month + 12.69%
  • Over 3 Month + 8.95%
  • Over 6 Month + 4.53%
  • Over 1 Year -1.98%

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 44.5
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 37,018
  • P/B Ratio
  • Average True Range
  • 48.06
  • EPS
  • 39.02
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 27.75
  • RSI
  • 60.73
  • MFI
  • 52.88

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,459.10
+ 4.5 (0.31%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,411.60
  • 50 Day
  • ₹1,379.33
  • 100 Day
  • ₹1,377.60
  • 200 Day
  • ₹1,387.04

Resistance and Support

1446.2 Pivot Speed
  • R3 1,523.90
  • R2 1,493.70
  • R1 1,476.40
  • S1 1,428.90
  • S2 1,398.70
  • S3 1,381.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Ltd. is a global pharmaceutical company, producing over 350 formulations and 80 APIs. Operating in 120+ countries, it leads in therapeutic areas like pain, rheumatology, and antimalarials, with fully-automated facilities approved by global regulatory bodies.

Ipca Laboratories has an operating revenue of Rs. 9,357.41 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 13% is healthy, ROE of 10% is good. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 7% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 17% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-11 Quarterly Results
2025-05-29 Audited Results & Final Dividend
2025-02-13 Quarterly Results
2024-11-14 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-08-05 FINAL Rs.2.00 per share(200%)Final Dividend
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
View Ipca Laboratories Dividend History Arrow
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories F&O

Ipca Laboratories Shareholding Pattern

44.72%
30.04%
5.99%
10.42%
0%
6.55%
2.28%

About Ipca Laboratories

  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Managing Director & CFO
  • Mr. Ajit Kumar Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,459 As on 06 December, 2025 | 04:22

The Market Cap of Ipca Laboratories is ₹37018 Cr As on 06 December, 2025 | 04:22

The P/E ratio of Ipca Laboratories is 44.5 As on 06 December, 2025 | 04:22

The PB ratio of Ipca Laboratories is 5.3 As on 06 December, 2025 | 04:22

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23